People · Operator
Named in public records as an officer, director or promoter · active 2021–2023 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Avenzo Therapeutics, Inc. | — | Biotechnology | Series D+ | $270.6M | $355.7M | 2022 |
| Alumis Inc. | — | Biotechnology | Series D+ | $240.0M | $433.1M | 2021 |
| Remix Therapeutics, Inc. | — | Biotechnology | Series A | $13.7M | $93.0M | 2023 |
Michael Rome at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Michael Rome on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Carl Gordon | 1 | 24 |
| Kevin Bitterman | 1 | 15 |
| Srinivas Akkaraju | 1 | 10 |
| Peter Smith | 1 | 9 |
| Simeon George | 1 | 8 |
| Judith Li | 1 | 8 |
| Richard Gaster | 1 | 7 |
| Alan Colowick | 1 | 7 |
| James Tananbaum | 1 | 6 |
| Jeff Goater | 1 | 4 |
| James B. Tananbaum | 1 | 4 |
| Mark Bradley | 1 | 3 |
| Patrick Machado | 1 | 3 |
| Matthew Patterson | 1 | 3 |
| Sapna Srivastava | 1 | 3 |
| June Lee | 1 | 3 |
| Vikram Bajaj | 1 | 3 |
| Garry Nicholson | 1 | 3 |
| Alan B. Colowick | 1 | 3 |
| Mohammad Hirmand | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.